NIH Funding Opportunities and Notices
- Notice of Correction to the Eligible Organizations Section of ORIP's PAR-24-265: Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed) November 4, 2024Notice NOT-OD-25-019 from the NIH Guide for Grants and Contracts
- Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) November 4, 2024Funding Opportunity PAR-25-225 from the NIH Guide for Grants and Contracts. Reissue PAR-21-122. This NOFO provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include […]
- Combating Antibiotic-Resistant Bacteria Interdisciplinary Units (CARBIRUs) (P01 Clinical Trial Not Allowed) November 4, 2024Funding Opportunity RFA-AI-24-074 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support multidisciplinary research programs focused on discovery to early development research to inform new approaches to prevent, diagnose, and treat antibiotic-resistant bacterial infections.
- Reminder to AHRQ Grantees that FY2020 Funds will Expire on September 30, 2025 November 4, 2024Notice NOT-HS-25-008 from the NIH Guide for Grants and Contracts
- NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) November 4, 2024Funding Opportunity PAR-25-139 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent […]
- Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional) November 4, 2024Funding Opportunity RFA-DA-26-019 from the NIH Guide for Grants and Contracts. Emerging threats continuously evolve. Xylazine, nitazenes, and other future threats are making their way or are already in the drug supply. Understanding them requires analyzing real world samples. Typically, testing strips are used to detect drug for which such strip exists, as the strips […]
- Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R43/R44 - Clinical Trials Optional) November 4, 2024Funding Opportunity RFA-DA-26-018 from the NIH Guide for Grants and Contracts. Emerging threats continuously evolve. Xylazine, nitazenes, and other future threats are making their way or are already in the drug supply. Understanding them requires analyzing real world samples. Typically, testing strips are used to detect drug for which such strip exists, as the strips […]
- Notice of Change to the Eligibility of Foreign Components in RFA-OD-24-010 "Building Sustainable Software Tools for Open Science (R03 Clinical Trial Not Allowed)" November 4, 2024Notice NOT-OD-25-018 from the NIH Guide for Grants and Contracts